An observational study in Heart Failure With Preserved Ejection Fraction and Prognathism, sponsored by Chongqing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-23.
Sponsored by Chongqing Medical University · Observational
Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied. Previous studies have found that elevated serum total bilirubin levels are associated with cardiac death, heart failure readmission, and all-cause mortality in patients with chronic heart failure. However, the relationship between direct bilirubin and prognosis in patients with HFpEF is unclear.
Patients with heart failure with preserved ejection fraction account for approximately 50% of all heart failure patients, have approximately 1.4 hospitalisations per year and an annual mortality rate of approximately 15%. Till now, there have no definitively proven therapies that can reduce their morbidity and mortality, HFpEF Patients have a poor prognosis. The current study found that the prognosis of patients with HFpEF may be related to the heterogeneity of the disease, its various phenotypes and multifactorial pathophysiology, which has not been fully elucidated. The current study found that bilirubin is a risk factor for adverse outcomes of various HFpEF-related complications, but the relationship between direct bilirubin and prognosis of HFpEF has not been reported. Therefore the investigators speculate that direct bilirubin is a predictor of prognosis of HFpEF patients.
11 studies on the registry are indexed under Prognathism; 6 are open to participants now.
Browse Prognathism studies →Chongqing Medical University is the lead sponsor of 78 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
heart failure with preserved ejection fraction (HFpEF)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnostic criteria including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
heart failure with preserved ejection fraction patients with direct bilirubn ≤6.8µmol/L
heart failure with preserved ejection fraction patients with direct bilirubn \>6.8µmol/L
The level of direct bilirubin
The level of direct bilirubin
Time frame: The day when patients on admission
a composite of heart failure rehospitalization or all-cause mortality
a composite of heart failure rehospitalization or all-cause mortality
Time frame: In an average of 3 year after discharge
heart failure rehospitalization
heart failure rehospitalization
Time frame: In an average of 3 year after discharge
all-cause mortality
all-cause mortality
Time frame: In an average of 3 year after discharge
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chongqing Medical University